Brand Companies at Risk for Products Manufactured by Generic Firms: California's Conte v. Wyeth Decision
Product Details
Brand drugmakers were stunned last month when California’s First District Court of Appeals ruled in Conte v. Wyeth that they can now be held liable for injuries caused by competing companies’ generic products.
This controversial ruling means you’d better be prepared for a slew of new claims. Plaintiff attorneys will not only attempt to get their cases heard in California state courts, but its expected that many states will follow suit.
Don’t wait to see what happens next. You need to take charge now to prepare for future claims ... act fast to build a strong preemption defense ... retool all your regulatory and legal strategies to meet the latest legal game changer.
And here’s the best place to start …
Veteran attorney Kelly Savage will explain exactly what Conte v. Wyeth ruling means to you. She’ll clarify when and how to raise a preemption defense and arm you with from-the-trenches legal strategies that can help you defuse lawsuits and defend yourself.
Order now for your entire team to learn:
- How the Conte v. Wyeth ruling can put your company at risk for products manufactured by generic firms
- Steps to take immediately to prepare for future claims by plaintiffs
- How to leverage your case into federal court — and why to do it
- Tips for evaluating whether to assert a preemption defense
- Battle-tested strategies for developing and asserting a preemption defense
- How to counter a plaintiff’s “changes being effected” argument that drugmakers can make labeling changes before FDA approval
- The FDA’s current position — and goals — on preemption
- And more!